



PRESS KIT

CAMPTON DIAGNOSTICS GMBH

COMPANY PROFILE

About CAMPTON Diagnostics GmbH

CAMPTON Diagnostics GmbH was spun off from the Fraunhofer Institute for Silicon Technology (ISIT) in Itzehoe in 2016.

The company develops and markets complete measuring systems for point-of-care diagnostics, i.e. for on-site examinations of patients. CAMPTON Diagnostics combines biotechnological and engineering know-how under one roof.

The "Biochip Reader" device developed by CAMPTON uses silicon-based biochips from Fraunhofer ISIT. The ISIT produces these in the institute's own clean room.

The system, which is based on "electrical biochip technology", can be used to obtain reliable information on the indication of infections, cancer or other diseases from a drop of whole blood within a few minutes. The tests are particularly fast, highly sensitive and enable the simultaneous measurement of several parameters in one sample.

Disposable cartridges with an integrated biochip are used for the measurements. The biochip functions like a conventional ELISA test, but is electrically readable and therefore extremely miniaturizable. The "Biochip Reader" performs the measurement fully automatically. After a few minutes, the analysis result is shown on the display as a real value.

CAMPTON Diagnostics is based in Itzehoe and has a strategic technology partnership with the Fraunhofer Institute for Silicon Technology (ISIT). In a second round of financing (Series A financing), Adolf Würth GmbH & Co. KG has invested in the company.

Further information can be found at www.campton-diagnostics.com.

Press contact Campton Diagnostics GmbH

Karin van Soest-Schückhaus, marvice GmbH, Mobile: 0172-2524 845, Phone: 02161-8269743
E-Mail: pressestelle@marvice.de

FACTS & FIGURES

Year of foundation:	2016
Management:	Jürgen Brink (CEO) Dr. Eric Nebling (CSO) Lars Blohm (CTO)
Associates	Jürgen Brink Dr. Eric Nebling Lars Blohm Jörg Albers DDr. Karl Gollegger Adolf Würth GmbH & Co. KG
Advisory council	DDr. Karl Gollegger Alexander Gerfer Dr. Axel Müller-Groeling Niels Ahlmann-Ohlsen
Business divisions:	Point-of-care diagnostics: <ul style="list-style-type: none"> • Human diagnostics <p>Further possible areas of application:</p> <ul style="list-style-type: none"> • Veterinary Diagnostics • Food diagnostics
Employees:	The establishment of an interdisciplinary team for the certified development and manufacture of medical products at the Itzehoe site is in progress. Current number of employees: 5 (approx. 9 by the end of 2019)
Corporate philosophy:	Improve patient care and treatment through point-of-care diagnostics to identify cancer, infectious and autoimmune diseases in doctors' offices, hospitals and clinics worldwide.
Technology partner:	Fraunhofer ISIT, Itzehoe
Production site:	Itzehoe
Products:	Campton Biochip Reader 100 Further generations in planning: <ul style="list-style-type: none"> • Campton Biochip Reader 250 (mobile technology) • Campton Biochip Reader 300 (smartphone-controlled technology)

FACTS & FIGURES

Areas of application:

With just one drop of blood, reliable, rapid analyses can be performed for many different diseases, for example:

- Allergies (food allergies, environmental allergies)
- Infectious diseases (borreliosis, malaria, ebola, hepatitis, HIV, zika, etc.)
- Oncology (early detection of cancer, therapy monitoring)
- autoimmune diseases
- cardiovascular diseases

The use of the biochip system is not limited to the diseases mentioned above.

Press contact Campton Diagnostics GmbH

Karin van Soest-Schückhaus, marvice GmbH, Mobile: 0172-2524 845, Phone: 02161-8269743

E-Mail: pressestelle@marvice.de

MANAGEMENT PROFILES

Jürgen Brink **CEO**

Mr. Brink is a founding partner of CAMPTON Diagnostics and is responsible within the company for sales, finance, legal, human resources and IT.

Since 2006, Mr. Brink has been a managing partner of the management consultancy brink.corporate development GmbH, which specializes in corporate strategy, mergers and acquisitions (M&A) and financing with equity and debt capital.

Prior to this, Mr. Brink was responsible for projects in the areas of "acquisition and project financing, M&A transactions and IPO consulting" as project manager in various banks and an international auditing company for many years, before he was able to develop a portfolio of approx. 500 companies worldwide as Director Corporate Development/M&A of one of the larger German family-owned companies.

Lars Blohm **CTO / Technical Director**

After training as an industrial electronics engineer and studying electrical engineering, Lars Blohm joined eBiochip Systems GmbH in 2002 as an engineer, where he developed automated analytical systems with electrical biochips.

From 2009 to 2019 he worked as a scientist at the Fraunhofer Institute for Silicon Technology (ISIT). As project manager of public and industrial projects, he was particularly involved in the development and construction of integrated complete systems for biomedical and energy-efficient MEMS applications.

Since June 2019, he has been a founding partner of CAMPTON Diagnostics, where he is full-time Managing Director and Technical Director (CTO). Currently, he is responsible for the certified development, manufacture and marketing of medical systems for point-of-care diagnostics at CAMPTON Diagnostics.

MANAGEMENT PROFILES

Dr. Eric Nebling
CSO / Scientific Director

Dr. Eric Nebling studied chemistry in Hamburg and subsequently received his doctorate in biochemistry.

Since 1999 he was employed at the Fraunhofer Institute for Silicon Technology (ISIT) in the department "Biotechnical Microsystems" (BTMS) and worked on the development and optimization of biochemical test methods on electrical biochips. Dr. Nebling was responsible for various research projects and had been head of the department since 2008.

He is co-founder of CAMPTON Diagnostics GmbH and scientific director (CSO) of the company. Since June 2019, Dr. Nebling has been working full-time for CAMPTON Diagnostics GmbH.

Press contact Campton Diagnostics GmbH

Karin van Soest-Schückhaus, marvice GmbH, Mobile: 0172-2524 845, Phone: 02161-8269743
E-Mail: pressestelle@marvice.de

PRODUCT INFORMATION

CAMPTON Biochip Reader

The CAMPTON Biochip Reader takes POC diagnostics to the next level of laboratory testing and heralds a new era in mobile diagnostics. With just one drop of blood, our biochip reader delivers reliable, rapid analysis for many different diseases.

CAMPTON Biochip Readers help improve patient care and treatment.

POC Diagnostics

Leading scientists at the Fraunhofer Institute for Silicon Technology (ISIT) have developed a new point-of-care (POC) technology to identify cancer, infectious and autoimmune diseases in medical practices, hospitals and clinics worldwide.

POC diagnostics is a decentralized, patient-oriented test that is usually performed with portable devices. These tests provide rapid results to improve patient care and treatment.

The system solution is certified, produced and sold worldwide by CAMPTON Diagnostics. The relevant technology is patented by Fraunhofer and exclusively licensed worldwide by CAMPTON Diagnostics.

Advantages of the CAMPTON Biochip Reader System

The detection of biomarkers in a blood sample from patients is currently based on immunological tests ("Enzyme-Linked ImmunoSorbent Assay" [ELISA] and "Recombinant Immunoblot Assay" [RIA]). These tests usually require laboratories, trained personnel and are time-consuming (hours to days to obtain results).

Portable diagnostic devices such as the CAMPTON Biochip Reader offer a much faster test result, which is very advantageous in the field of medical care. The advantage of the system for the end customer (as well as for our direct customers, physicians and hospitals) is that it is less costly and takes less time. It takes less than 15 minutes to perform the test and get the results.

The system is deliberately designed to identify diseases with different biological substances. Competitors often use optical systems to detect diseases, while the newly developed CAMPTON technology uses electrical signals. This means that CAMPTON technology is more robust and suitable for use in virtually any climate.

PRODUCT INFORMATION

The Technology

In addition to the wide range of possible customer-specific applications, the following tests are currently available for research and development:

- Hepatitis C Antibodies (HCV)
- C-reactive protein (CRP)
- Prostate-specific antigen (PSA)

Possible Applications for the Biochip System

- Allergies (food allergies, environmental allergies)
- Infectious diseases (borreliosis, malaria, ebola, hepatitis, HIV, zika, etc.)
- Oncology (early detection of cancer, therapy monitoring)
- autoimmune diseases
- cardiovascular diseases

The use of the biochip system is not limited to the diseases mentioned above. It is possible to integrate almost any ELISA-based test into the biochip platform as long as disease-specific proteins can be found in any type of body fluid.

PRODUCT INFORMATION



Press contact Campton Diagnostics GmbH

Karin van Soest-Schückhaus, marvice GmbH, Mobile: 0172-2524 845, Phone: 02161-8269743

E-Mail: pressestelle@marvice.de

PRESS RELEASE

CAMPTON Diagnostics wins the Würth Group as investor

Würth Group participates in second financing round of Campton Diagnostics. Newcomer On-site diagnostics help to identify diseases quickly and provide better care for patients

Itzehoe, 09.07.2019 - CAMPTON Diagnostics GmbH ("CAMPTON") was founded to further develop and market biochip-based in vitro diagnostics at the point of care. CAMPTON has now been able to win the Würth Group as an investor.

Prof. Dr. h. c. mult. Reinhold Würth, Chairman of the Supervisory Board of the Würth Group, supports this project. After promising preliminary negotiations, Prof. Würth personally visited CAMPTON Diagnostics GmbH at its location in the Fraunhofer ISIT in Itzehoe.

"I find the business model and the idea behind CAMPTON very convincing," emphasized Prof. Würth during his visit and gave his consent to the series A financing of the company by the Würth Group. This financing enables CAMPTON to act for the next few years.

"We are delighted to be working with such a renowned company as Adolf Würth GmbH & Co KG," said Jürgen Brink, Chief Executive Officer of CAMPTON.

CAMPTON is currently working on the development and certification of the first generations of devices for point-of-care diagnostics, e.g. on-site analysis directly at the patient. In connection with this, CAMPTON scientists develop tests which are to be realized and distributed together with interested partners from the fields of human diagnostics and bioanalytics.

Results in a few minutes: About CAMPTON Diagnostics GmbH

CAMPTON Diagnostics GmbH was spun off from the Fraunhofer Institute for Silicon Technology (ISIT) in Itzehoe in 2016. CAMPTON develops highly sensitive in-vitro diagnostics for which ISIT manufactures the biochips in the institute's own clean room.

Within a few minutes, the CAMPTON Point-of-Care system allows reliable statements to be made on the indication of infections, cancer or other diseases from a drop of whole blood. The robust system is portable, easy to operate and therefore very well suited for use independent of location - even directly at the patient's site. The technology is based on the so-called "electrical biochip technology".

Disposable cartridges with an integrated biochip are used for the respective measurements. The biochip functions like a conventional ELISA test, but can be read out electrically and is therefore enormously miniaturisable.

The device, the so-called reader, carries out the measurement fully automatically. Nothing more needs to be done except to take the sample with a lancet and insert the cartridge into the device. After a few minutes, the analysis result is shown on the display as a real value.

The CAMPTON platform technology with biochips enables universal use of the device. Only the packaging of the biochip determines which test is involved; the device and large parts of the required reagents remain identical.

The shareholders of CAMPTON Diagnostics GmbH were advised by b.cd GmbH as part of this transaction.

About Adolf Würth GmbH & Co. KG

Adolf Würth GmbH & Co KG is a leading specialist in assembly and fastening materials for professional applications. It is the largest individual company of the Würth Group, which operates worldwide. Adolf Würth GmbH & Co KG currently employs over 7,000 people throughout Germany and generated sales of EUR 1.98 billion (including intra-group sales) in the 2018 financial year.

About b.cd GmbH

b.cd GmbH sees itself as a corporate finance consultant for the solution of strategic and financial problems of entrepreneurs in owner-managed, medium-sized family businesses.

b.cd advises clients on mergers & acquisitions (M&A) decisions - acquisition and sale of companies, venture capital and private equity brokerage, joint ventures, mergers and acquisitions as well as debt financing of all kinds. Further information is available at www.brink.cd.de.

Press contact Campton Diagnostics GmbH

Karin van Soest-Schückhaus, marvice GmbH, Mobile: 0172-2524 845, Phone: 02161-8269743
E-Mail: pressestelle@marvice.de

PRESS RELEASE

Fraunhofer ISIT scientists and CURIT Biotech Holding GmbH establish CAMPTON Diagnostics UG

New On-Site Diagnostics Helps Quickly Identify Viral Diseases and Improve Patient Care

Itzehoe, 20.01.2017

CAMPTON Diagnostics UG was founded in 2016 as a spin-off from the Fraunhofer Institute for Silicon Technology and is now being launched. The company develops and markets complete measuring systems for point-of-care diagnostics, i.e. for on-site examinations of patients. The founders come from Fraunhofer ISIT and CURIT Biotech Holding GmbH. With the establishment of the company, they hope to advance the certification and market launch of their research products. The focus here is on rapid infection diagnostics for the detection of hepatitis, zika, ebola and malaria infections.

Jürgen Brink, Managing Director of CAMPTON Diagnostics UG, explains the potential of the new company: "In contrast to most devices on the market, ours is easy to use, with short analysis times of direct whole blood measurements. This enables fast and accurate on-site measurements for diagnosis, but also for therapy monitoring, e.g. for general practitioners.

CAMPTON Diagnostics UG combines biotechnological and engineering know-how under one roof. The current biochip platform from Fraunhofer ISIT is used for this point-of-care diagnostic developed by CAMPTON. The tests are particularly fast, highly sensitive and enable the simultaneous measurement of several parameters in one sample with a mobile complete system.

ISIT directors Dr. Axel Müller-Groeling and Prof. Dr. Wolfgang Benecke are also optimistic about the company's future: "We are delighted with the establishment of CAMPTON Diagnostics UG and are convinced that the company will take a successful path. Fraunhofer ISIT expressly supports the new company in its plans and in joint projects."

CAMPTON Diagnostics UG is currently planning to establish an interdisciplinary team at the Itzehoe site for the certified development and manufacture of its medical products. Once the device has been approved as a medical device, the company plans to start manufacturing and marketing biochips. In two to three years, the founders intend to bring more than 100,000 biochips per year to the diagnostics market. The company is interested in strategic partnerships for the development of new tests and the expansion of production capacities.

About the Fraunhofer Institute for Silicon Technology (ISIT)

The Fraunhofer ISIT in Itzehoe is one of Europe's most modern research facilities for microelectronics and microsystems technology. At the heart of the institute are the cleanroom facilities, large enough not only to carry out research, but also to manufacture the microchips developed on an industrial scale.

In close cooperation with partners from industry, 190 scientists at ISIT develop power electronic components and microsystems with fine moving structures for sensor technology (pressure, motion, biochemical analysis, etc.) and actuators (valves, scanners, mirror arrays, etc.), including the necessary housing technology.

About CURIT Biotech Holding GmbH

CURIT Biotech Holding GmbH is a private holding company and participates in interesting start-up companies and projects in the field of medical biotechnology.

The products to be exploited are antibody-based biological tests for in vitro diagnostic systems and immunocytological or immunohistochemical applications. On the other hand, they are antibody-based, targeted therapeutics for the treatment of various human diseases.

press contact**CAMPTON Diagnostics UG**

Lars Blohm
Managing Director (CTO)
Fraunhoferstrasse 1
25524 Itzehoe

Phone: +49 4821 - 17 4321
E-mail: blohm@campton-diagnostics.com
Internet: www.campton-diagnostics.com

CURIT Biotech Holding GmbH


Jürgen Brink
Managing Director (CEO)
Albertus road 44a
41061 Mönchengladbach, Germany

Phone: +49 2161 - 29 33 000
E-mail: brink@curit-biotech.com
Internet: www.curit-biotech.com

Fraunhofer Institute for Silicon Technology

Claus Wacker
Press and public relations work
Fraunhoferstrasse 1
25524 Itzehoe

phone: +49 4821/17-4214
E-mail: claus.wacker@isit.fraunhofer.de
Internet: www.isit.fraunhofer.de



Left: Electric biochip for multiparameter diagnostics.

Right: Portable meter with reagent block and disposable measuring cartridge.